[
    {
        "molecule_name": "trans-2-arylcyclopropylamine analogues",
        "protein_target_name": "LSD1",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "Ki",
        "value": "188-566",
        "unit": "micromolar",
        "is_logarithmic": false,
        "raw_mentions": "Gooden et al. reported trans-2-arylcyclopropylamine analogues that inhibit LSD1 with Ki values in the range of 188-566 micromolar.\nUeda et al. ((2009) J. Am. Chem Soc. 131(48):17536-17537) reported cyclopropylamine analogs selective for LSD1 over MAO-A and MAO-B that were designed based on reported X-ray crystal structures of these enzymes with a phenylcyclopropylamine-FAD adduct and a FAD-N-propargyl lysine peptide; the reported IC50 values for phenylcyclopropylamine were about 32 micromolar for LSD1 whereas compounds 1 and 2 had values of 2.5 and 1.9 micromolar respectively."
    },
    {
        "molecule_name": "phenylcyclopropylamine",
        "protein_target_name": "LSD1",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "IC50",
        "value": "32",
        "unit": "micromolar",
        "is_logarithmic": false,
        "raw_mentions": "Gooden et al. reported trans-2-arylcyclopropylamine analogues that inhibit LSD1 with Ki values in the range of 188-566 micromolar.\nUeda et al. ((2009) J. Am. Chem Soc. 131(48):17536-17537) reported cyclopropylamine analogs selective for LSD1 over MAO-A and MAO-B that were designed based on reported X-ray crystal structures of these enzymes with a phenylcyclopropylamine-FAD adduct and a FAD-N-propargyl lysine peptide; the reported IC50 values for phenylcyclopropylamine were about 32 micromolar for LSD1 whereas compounds 1 and 2 had values of 2.5 and 1.9 micromolar respectively."
    },
    {
        "molecule_name": "compound 1",
        "protein_target_name": "LSD1",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "IC50",
        "value": "2.5",
        "unit": "micromolar",
        "is_logarithmic": false,
        "raw_mentions": "Gooden et al. reported trans-2-arylcyclopropylamine analogues that inhibit LSD1 with Ki values in the range of 188-566 micromolar.\nUeda et al. ((2009) J. Am. Chem Soc. 131(48):17536-17537) reported cyclopropylamine analogs selective for LSD1 over MAO-A and MAO-B that were designed based on reported X-ray crystal structures of these enzymes with a phenylcyclopropylamine-FAD adduct and a FAD-N-propargyl lysine peptide; the reported IC50 values for phenylcyclopropylamine were about 32 micromolar for LSD1 whereas compounds 1 and 2 had values of 2.5 and 1.9 micromolar respectively."
    },
    {
        "molecule_name": "compound 2",
        "protein_target_name": "LSD1",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "IC50",
        "value": "1.9",
        "unit": "micromolar",
        "is_logarithmic": false,
        "raw_mentions": "Gooden et al. reported trans-2-arylcyclopropylamine analogues that inhibit LSD1 with Ki values in the range of 188-566 micromolar.\nUeda et al. ((2009) J. Am. Chem Soc. 131(48):17536-17537) reported cyclopropylamine analogs selective for LSD1 over MAO-A and MAO-B that were designed based on reported X-ray crystal structures of these enzymes with a phenylcyclopropylamine-FAD adduct and a FAD-N-propargyl lysine peptide; the reported IC50 values for phenylcyclopropylamine were about 32 micromolar for LSD1 whereas compounds 1 and 2 had values of 2.5 and 1.9 micromolar respectively."
    },
    {
        "molecule_name": "tranylcypromine (TCPA)",
        "protein_target_name": "LSD1",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "IC50",
        "value": "low nanomolar range",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "FIG. 1 summarizes structure-activity relationship evolution of increased potency towards LSD1 as compared to MAOA and/or MAOB from compounds that were not selective (e.g., tranylcypromine (TCPA)) to compounds that are selective inhibitors of LSD1 with IC50 values in the low nanomolar range.\nFIG. 2 summarizes structure-activity relationship evolution of increased potency towards LSD1 and MAOB as compared to MAOA from compounds that were not selective for LSD1 and MAOB (e.g., tranylcypromine (TCPA)). The dual LSD1/MAOB compounds have IC50 values for these two targets in the low nanomolar range.\nFIG. 3 shows the results of a western blot stained for H3K4 methylation with SH-SYSY cells grown in the presence of Compound Dual-1(at 100 μM) or parnate (“PNT”) (at 250 μM) for 1, 2, and 3 days, showing that this compound, Dual-1, increases H3K4 methylation in cells in a time dependent manner."
    },
    {
        "molecule_name": "tranylcypromine (TCPA)",
        "protein_target_name": "LSD1 and MAOB",
        "protein_uniprot_id": null,
        "protein_seq_id": null,
        "binding_metric": "IC50",
        "value": "low nanomolar range",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "FIG. 1 summarizes structure-activity relationship evolution of increased potency towards LSD1 as compared to MAOA and/or MAOB from compounds that were not selective (e.g., tranylcypromine (TCPA)) to compounds that are selective inhibitors of LSD1 with IC50 values in the low nanomolar range.\nFIG. 2 summarizes structure-activity relationship evolution of increased potency towards LSD1 and MAOB as compared to MAOA from compounds that were not selective for LSD1 and MAOB (e.g., tranylcypromine (TCPA)). The dual LSD1/MAOB compounds have IC50 values for these two targets in the low nanomolar range.\nFIG. 3 shows the results of a western blot stained for H3K4 methylation with SH-SYSY cells grown in the presence of Compound Dual-1(at 100 μM) or parnate (“PNT”) (at 250 μM) for 1, 2, and 3 days, showing that this compound, Dual-1, increases H3K4 methylation in cells in a time dependent manner."
    }
]